Product Images Pregabalin

This is a medication prescription for Pregabalin Capsules, USP used as a treatment for certain types of nerve pain. Each capsule contains 25mg of Pregabalin, and this medication should be kept out of the reach of children. There are 30 capsules per prescription and it should be stored at a room temperature of 20°-25°C (68°-77°F). The National Drug Code (NDC) for this medication is 63629-8199-01.*

This appears to be a label containing information about a medication. It compares the medication to "Lyrica 25mg," giving information about the dosage and form of the medication (capsule) as well as the manufacturer and expiration date. The medication should be stored at room temperature and kept out of reach of children.*

This appears to be a chart or table showing the percentage of patients who have improved with a particular treatment (potentially Pregabalin 160 mg) over a course of 3 days. It also includes some numbers that may be associated with measuring pain improvement from baseline. However, the chart lacks clear labels and has some stray characters that make it difficult to interpret.*

This is a report with data on percent of improvement in patients' pain after taking different medications. It includes the names of the medications and their corresponding dosages. However, the formatting and text is not clear enough to provide a more detailed description.*

This is a report of a clinical trial comparing the efficacy of Fregabalin 100 mg, Pregataiin 80 mg, and placebo in reducing pain. The number of patients who improved with each treatment is not clear from the text. However, a chart showing the percent improvement in pain from baseline ranges from 0.8% to 38.8%.*

This document appears to show estimated percentages of subjects without "LTR" (unclear what this abbreviation means without more context) for a given treatment. The treatment options listed are "Progabain" and "Placebo" and the percentages range from 0% to 100%, with intervals of 10%. The document also displays a chart with days on the x-axis and percentages on the y-axis. However, without more information or context it is difficult to determine the purpose or significance of this information.*

The text shows a chart that indicates the percentage of subjects that were improved after 16 weeks of treatment with either pregabalin or a placebo. The percentage of subjects improved after taking pregabalin is not specified, but the chart shows that 100% of subjects taking a placebo were improved. The chart also displays various numerical values ranging from 200 to 280.*

This appears to be a formula for calculating creatinine clearance, a measure of kidney function. The formula involves subtracting the patient's age in years multiplied by 140 from their weight in kilograms, and then multiplying that result by their serum creatinine level in mg/dL. For female patients, the product is then multiplied by 0.85.*